Smartin is an innovative biotech company focused on developing groundbreaking cancer therapeutics and ophthalmology treatments. Our research centers around targeting the mitochondrial chaperone TRAP1, addressing the limitations of current therapies for chemoresistant cancers and retinopathies. Our portfolio includes several notable drugs:

• Gamitrinib: The first TRAP1 inhibitor (J. Clin. Invest. 2009).
• DN401: The first inhibitor targeting both Hsp90 and TRAP1 (J. Med. Chem. 2017).
• SMX and its derivatives: The first client mimic inhibitor with exceptional TRAP1 inhibitory activities (J. Med. Chem. 2022).

Our vision is to revolutionize mitochondrial-targeted therapies for intractable diseases. We strive to enhance patients’ quality of life by advancing treatments for chemoresistant cancers, retinopathies, and other mitochondria-dysregulated human diseases. Smartin’s mission is to pioneer effective solutions that go beyond conventional approaches.

Noteworthy Points:

• Founded in 2019, Smartin built upon foundational research conducted at UNIST on TRAP1 biology and inhibitor development.
• CEO Dr. Byoung Heon Kang, a professor at UNIST, possesses two decades of expertise in TRAP1 biology and inhibitor research.
• Our research team collaborates with UNIST on a novel mitochondrial targeting system for safe and effective drug delivery to mitochondria.